Priming of HIV-1-specific CD8+ T cells with strong functional properties from naïve T cellsResearch in context

• Published in: EBioMedicine Vol. 42; pp. 109 - 119
• Main Authors: Nozomi Kuse, Xiaoming Sun, Tomohiro Akahoshi, Anna Lissina, Takuya Yamamoto, Victor Appay, Masafumi Takiguchi
• Format: Journal Article
• Language: English
• Published: Elsevier 01.04.2019
• ISSN: 2352-3964; 2352-3964

Background: HIV-1-specific CD8+ T cells are required for immune suppression of HIV-1 replication and elimination of the associated viral reservoirs. However, effective induction of functional HIV-1-specific CD8+ T cells from naïve cells remains problematic in the setting of human vaccine trials. In this study, we investigated priming of functional HIV-1-specific CD8+ T cells from naïve cells. Methods: HIV-1-specific CD8+ T cells were primed from naïve T cells of HIV-1-seronegative individuals using TLR4 ligand LPS or STING ligand 3′3′-cGAMP in vitro. We established HIV-1-specific CD8+ T cell lines from primed T cells and then investigated functional properties of these cells. Findings: HIV-1-specific CD8+ T cells primed with LPS failed to suppress HIV-1. In contrast, 3′3′-cGAMP effectively primed HIV-1-specific CD8+ T cells with strong ability to suppress HIV-1. 3′3′-cGAMP-primed T cells had higher expression levels of perforin and granzyme B than LPS-primed ones. The expression levels of granzyme B and perforin and viral suppression ability of 3′3′-cGAMP-primed T cells were positively correlated with the production level of type I IFN from PBMCs stimulated with 3′3′-cGAMP. Interpretation: The present study demonstrates the potential of 3′3′-cGAMP to induce HIV-1-specific CD8+ T cells with strong effector function from naïve cells via a strong type I IFN production and suggests that this STING ligand may be useful for AIDS vaccine and cure treatment. Keywords: HIV-1, CD8+ T cells, Priming, STING ligand, Naïve T cell